Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Ioannou N, Hagner PR, Stokes M, Gandhi AK, et al. Blood 2021;137:216-231.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ioannou N, Hagner PR, Stokes M, Gandhi AK, et al. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood 2021;137:216-231.
PMID: 33024998